A judge has refused an application by generic drug maker Juno Pharmacueticals to withdraw an admission in a battle with Millennium Pharmaceuticals over its cheap version of breakthrough cancer drug Velcade, denying Juno a potential defence to allegations of patent infringement.
Horse vaccine maker Zoetis has appealed a ruling that denied its request for $450,000 as security for costs in an unfunded class action accusing it of failing to warn about the vaccine’s side effects.
The founder and former CEO of Smiles Inclusive has been taken to court by the dental company, which accuses him of serious misconduct over allegedly unlawful payments and transactions.
The Australian Competition and Consumer Commission has brought legal action against Bupa alleging the aged care provider charged thousands of residents for promised extra services it did not provide.
Generic drug maker Sandoz has secured a retroactive licence to manufacture a cheaper version of top-selling antidepressant Lexapro, the drug at the heart of a long-running patent infringement battle with pharmaceutical giant Lundbeck.
A judge has denied Mylan’s bid to temporarily block Sun Pharma and Cipla from making generic versions of anti-cholesterol drug Lipidil while it appeals a ruling invalidating several claims of its patents for the drug, citing the “difficulty, complexity and uncertainty” in assessing compensation under an undertaking as to damages in pharmaceutical patent proceedings.
F. Hoffman La-Roche has reached a settlement in a patent lawsuit over Sandoz’s plan to market a biosimilar version of its patented biologic used to treat various cancers and rheumatoid arthritis.
Global pharmaceutical giant Lundbeck has launched a bid to escape a prior undertaking blocking it from appealing a court’s decision that allowed four generic drug makers to apply for licences to manufacture generic versions of popular antidepressant Lexapro.
Two generic pharmaceutical companies, Generic Partners and Apotex, have filed cross-claims alleging that Neurim Pharmaceuticals’ patent for its insomnia drug Circadin is invalid and should be revoked.
IP Australia has ordered biotech firm MacroGenics to amend its patent for a type of polypeptide used in treatments for cancer, autoimmune disorders and other diseases after a successful opposition from the chairman of intellectual property boutique Wrays.